Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 MetaVia Inc. (NASDAQ:MTVA) is currently conducting a Phase 1 clinical trial of DA-1726 in patients with obesity. In September 2024, ...
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that coincides with disappointing obesity sales and a leadership shake-up. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback